Published in J Proteomics on March 24, 2010
Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J (2012) 0.87
Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression. Cells (2014) 0.76
SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients. Int J Proteomics (2015) 0.75
Quantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line. Int J Mol Sci (2014) 0.75
The intimate and controversial relationship between voltage-gated proton channels and the phagocyte NADPH oxidase. Immunol Rev (2016) 0.75
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79
cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell (2011) 4.78
The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell (2011) 4.43
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet (2008) 4.37
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood (2008) 3.85
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood (2009) 3.50
BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood (2011) 2.68
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45
Reconstitution of the death-inducing signaling complex reveals a substrate switch that determines CD95-mediated death or survival. Mol Cell (2009) 2.24
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood (2009) 2.22
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood (2006) 2.10
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood (2010) 2.09
Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood (2006) 1.74
HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. Nat Immunol (2010) 1.70
MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood (2003) 1.69
A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol Cell (2012) 1.64
Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma (2004) 1.51
Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood (2005) 1.51
Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. Oncogene (2003) 1.49
Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells. Mol Cancer (2006) 1.48
A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One (2009) 1.48
A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci. Am J Hum Genet (2005) 1.43
Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood (2002) 1.40
Voltage-gated proton channels maintain pH in human neutrophils during phagocytosis. Proc Natl Acad Sci U S A (2009) 1.39
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood (2002) 1.38
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol (2009) 1.34
A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood (2007) 1.32
Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene (2002) 1.31
TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res (2005) 1.29
Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet (2004) 1.27
Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood (2012) 1.26
Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res (2006) 1.22
High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood (2002) 1.22
Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. Blood (2002) 1.21
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica (2010) 1.17
Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res (2010) 1.12
Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood (2005) 1.11
t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood (2007) 1.10
Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol (2007) 1.09
Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics (2009) 1.07
Identification of Thr29 as a critical phosphorylation site that activates the human proton channel Hvcn1 in leukocytes. J Biol Chem (2009) 1.07
The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics. FASEB J (2005) 1.07
Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer (2014) 1.06
Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus. Hum Mol Genet (2010) 1.02
pH regulation and beyond: unanticipated functions for the voltage-gated proton channel, HVCN1. Trends Cell Biol (2010) 1.01
High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma. Br J Haematol (2012) 1.00
Caspase-7 is directly activated by the approximately 700-kDa apoptosome complex and is released as a stable XIAP-caspase-7 approximately 200-kDa complex. J Biol Chem (2005) 1.00
ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol (2013) 0.99
Diarylurea compounds inhibit caspase activation by preventing the formation of the active 700-kilodalton apoptosome complex. Mol Cell Biol (2003) 0.98
Pro-apoptotic proteins released from the mitochondria regulate the protein composition and caspase-processing activity of the native Apaf-1/caspase-9 apoptosome complex. J Biol Chem (2004) 0.98
The C-terminal tail of the M3-muscarinic receptor possesses anti-apoptotic properties. J Biol Chem (2003) 0.98
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol (2007) 0.98
Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol (2011) 0.96
Regulation of casein kinase-2 (CK2) activity by inositol phosphates. J Biol Chem (2004) 0.94
Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer (2002) 0.94
Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer (2007) 0.94
CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res (2010) 0.93
Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma--a phase II trial. Br J Haematol (2014) 0.93
Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia. Br J Haematol (2007) 0.92
ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica (2011) 0.91
Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer (2006) 0.91
Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. Blood (2008) 0.91
Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination. J Neuropathol Exp Neurol (2006) 0.90
BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism. Blood (2007) 0.90
The CBFA2T3/ACSF3 locus is recurrently involved in IGH chromosomal translocation t(14;16)(q32;q24) in pediatric B-cell lymphoma with germinal center phenotype. Genes Chromosomes Cancer (2012) 0.90
GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haematol (2008) 0.90
Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. Mol Cancer Ther (2009) 0.90
Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma. Proc Natl Acad Sci U S A (2006) 0.90
Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia. Blood (2009) 0.89
Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing. Br J Haematol (2009) 0.89
Characterization of the transforming growth factor-beta 1-induced apoptotic transcriptome in FaO hepatoma cells. J Biol Chem (2002) 0.88
Loss of thymidine kinase 2 alters neuronal bioenergetics and leads to neurodegeneration. Hum Mol Genet (2010) 0.88
Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med (2014) 0.87
Glucose--a sweet way to die: metabolic switching modulates tumor cell death. Cell Cycle (2012) 0.86
Primary lymphoma-like lesions of the uterine cervix; sheep in wolves' clothing. Br J Haematol (2011) 0.84
Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia. Br J Haematol (2013) 0.84
p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia. Blood (2009) 0.84
Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies. Blood (2010) 0.84
Caspase-9 cleavage, do you need it? Biochem J (2007) 0.83
The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem Biophys Res Commun (2011) 0.83
TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome. Br J Haematol (2011) 0.83
Caspase cleavage of Itch in chronic lymphocytic leukemia cells. Biochem Biophys Res Commun (2008) 0.83
Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia. Br J Haematol (2014) 0.82
t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. Blood (2012) 0.82
Bilateral subdural hygromas following intrathecal methotrexate. Br J Haematol (2011) 0.81
Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma. Haematologica (2009) 0.81
Alemtuzumab-resistant Sézary syndrome responding to zanolimumab. Br J Haematol (2011) 0.81
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol (2013) 0.81
Isolation, characterisation and reconstitution of cell death signalling complexes. Methods (2013) 0.80
Cloning of immunoglobulin chromosomal translocations by long-distance inverse polymerase chain reaction. Methods Mol Med (2005) 0.80
Early failure of N-methyl-D-aspartate receptors and deficient spine formation induced by reduction of regulatory heme in neurons. Mol Pharmacol (2011) 0.79
Regulation of apoptosis by peroxisome proliferators. Toxicol Lett (2004) 0.78
Interphase cytogenetic characterization of aberrations in the long arm of chromosome 1 in B-cell lymphoid malignancies. Cancer Genet Cytogenet (2003) 0.78
Proteomic analysis of cell surface membrane proteins in leukemic cells. Methods Mol Biol (2007) 0.77
Additional precursor purification in isobaric mass tagging experiments by traveling wave ion mobility separation (TWIMS). J Proteome Res (2014) 0.77